Guggenheim S&P 500® Eq Weight HC ETF
Estimates and Recommendations for DaVita on September 17
Analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017.
Allergan Unveils Spotlyte, Its First Digital Ventures Launch
On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit.
Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).
Changes in Bristol-Myers Squibb’s Profitability in 2016
Bristol-Myers Squibb (BMY) reported a rise of 17% in revenue to ~$19.4 billion in 2016, compared to $16.6 billion in 2015. The company reported a net profit of ~$4.5 million in 2016.
A Look at Johnson & Johnson’s Valuation ahead of Its 2Q16 Results
Due to Johnson & Johnson’s wide geographic presence, expansive product portfolio, and strong cash flow, its valuation multiple has witnessed a gradual rise.
Mapping Varian Medical Systems’ Geographic Strategy
Varian Medical Systems (VAR) is a global medical device company that generates ~50% of its total revenues from North America and 26% and 24% of total revenues from Europe and Asia, respectively.
What Is Medtronic’s Valuation ahead of 4Q16 Results?
Due to Medtronic’s strong fundamentals, the company’s valuation multiple has witnessed a gradual rise since its 3Q16 earnings release.
How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation
On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.
The Geographic Strategy of Thermo Fisher Scientific
Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.
Mapping Abbott Laboratories’ Geographic Strategy
Abbott Laboratories is a global healthcare company that sees 70% of its total revenues generated in markets outside the United States.
Analyzing Becton, Dickinson and Company’s Geographic Strategy
Becton, Dickinson and Company (BDX), or BD, has operations across the globe, with more than 50% of its 2015 revenues coming from international markets.
How Does Dentsply International Compare to Peers after 3Q15?
In this article, we’ll compare Dentsply against its peers and the ETFs that invest in Dentsply.